JP5945381B2 - タンパク質 - Google Patents

タンパク質 Download PDF

Info

Publication number
JP5945381B2
JP5945381B2 JP2009550765A JP2009550765A JP5945381B2 JP 5945381 B2 JP5945381 B2 JP 5945381B2 JP 2009550765 A JP2009550765 A JP 2009550765A JP 2009550765 A JP2009550765 A JP 2009550765A JP 5945381 B2 JP5945381 B2 JP 5945381B2
Authority
JP
Japan
Prior art keywords
cancer
ogta076
lymphocytic leukemia
antibody
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009550765A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010518847A5 (enExample
JP2010518847A (ja
Inventor
ロフルフフ クフリスチアン
ロフルフフ クフリスチアン
スタムプス アラスダイル
スタムプス アラスダイル
Original Assignee
オックスフォード ビオトヘラペウトイクス エルティーディー．
オックスフォード ビオトヘラペウトイクス エルティーディー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オックスフォード ビオトヘラペウトイクス エルティーディー．, オックスフォード ビオトヘラペウトイクス エルティーディー． filed Critical オックスフォード ビオトヘラペウトイクス エルティーディー．
Publication of JP2010518847A publication Critical patent/JP2010518847A/ja
Publication of JP2010518847A5 publication Critical patent/JP2010518847A5/ja
Application granted granted Critical
Publication of JP5945381B2 publication Critical patent/JP5945381B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pregnancy & Childbirth (AREA)
JP2009550765A 2007-02-26 2008-02-26 タンパク質 Active JP5945381B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US90350907P 2007-02-26 2007-02-26
US90351007P 2007-02-26 2007-02-26
US60/903,509 2007-02-26
US60/903,510 2007-02-26
GBPCT/GB2008/050124 2008-02-25
PCT/GB2008/050124 WO2008104803A2 (en) 2007-02-26 2008-02-25 Proteins
PCT/GB2008/050127 WO2008104806A2 (en) 2007-02-26 2008-02-26 Protein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014207923A Division JP2015091797A (ja) 2007-02-26 2014-10-09 タンパク質

Publications (3)

Publication Number Publication Date
JP2010518847A JP2010518847A (ja) 2010-06-03
JP2010518847A5 JP2010518847A5 (enExample) 2011-04-21
JP5945381B2 true JP5945381B2 (ja) 2016-07-05

Family

ID=39486447

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009550765A Active JP5945381B2 (ja) 2007-02-26 2008-02-26 タンパク質
JP2014207923A Withdrawn JP2015091797A (ja) 2007-02-26 2014-10-09 タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014207923A Withdrawn JP2015091797A (ja) 2007-02-26 2014-10-09 タンパク質

Country Status (13)

Country Link
US (4) US20100098628A1 (enExample)
EP (3) EP3118220B1 (enExample)
JP (2) JP5945381B2 (enExample)
CY (2) CY1118169T1 (enExample)
DK (3) DK3118220T3 (enExample)
ES (2) ES2599477T3 (enExample)
HR (2) HRP20161338T1 (enExample)
HU (2) HUE046149T2 (enExample)
LT (2) LT2441775T (enExample)
PL (2) PL3118220T3 (enExample)
PT (2) PT3118220T (enExample)
SI (2) SI3118220T1 (enExample)
WO (3) WO2008104803A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008104803A2 (en) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
MX341926B (es) 2008-08-28 2016-09-07 Astute Medical Inc Metodos y composiciones para la diagnosis y prognosis de daño renal y falla renal.
CA2735590A1 (en) 2008-08-29 2010-03-04 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ628843A (en) 2008-10-21 2016-02-26 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ592432A (en) 2008-11-03 2013-01-25 Alethia Biotherapeutics Inc Antibodies that specifically block the biological activity of a tumor antigen Kidney associated antigen 1 (KAAG1)
EP2361018B1 (en) 2008-11-10 2015-04-01 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
ES2574236T3 (es) * 2009-04-20 2016-06-16 Oxford Biotherapeutics Ltd Anticuerpos específicos para cadherina-17
WO2011017614A1 (en) * 2009-08-07 2011-02-10 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EA201290056A1 (ru) 2009-08-07 2012-08-30 Астьют Медикал, Инк. Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
US10324093B2 (en) 2009-11-07 2019-06-18 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ625423A (en) 2009-12-20 2015-02-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ601590A (en) 2010-02-05 2014-10-31 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2539712A4 (en) 2010-02-26 2013-09-18 Astute Medical Inc METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE
EP3339859A1 (en) 2010-06-23 2018-06-27 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2585827A4 (en) 2010-06-23 2013-12-04 Astute Medical Inc METHOD AND COMPOSITIONS FOR DIAGNOSIS AND FORECASTING kidney injury and kidney insufficiency
JP2012197258A (ja) * 2011-03-23 2012-10-18 Tohoku Univ 個別化治療診断のためのマーカータンパク質絶対量の定量方法
PT3173427T (pt) 2011-03-31 2019-09-17 Adc Therapeutics Sa Anticorpos contra antigénio associado ao rim 1 e fragmentos de ligação a antigénio dos mesmos
EP2758779B1 (en) * 2011-09-22 2017-09-06 Expression Pathology, Inc. Mrm/srm assay for death receptor 5 protein
EP2764082B1 (en) * 2011-10-04 2018-05-23 Expression Pathology, Inc. Srm/mrm assay for the ephrin type-a receptor 2 protein
ES2734494T3 (es) 2011-12-08 2019-12-10 Astute Medical Inc Métodos y usos para el diagnóstico de una lesión renal y de una insuficiencia renal
PT2802351T (pt) 2012-01-09 2019-06-27 Adc Therapeutics Sa Agentes para o tratamento de cancro da mama triplo negativo
CN107256329B (zh) 2012-01-19 2020-12-15 耐克创新有限合伙公司 用于检测用户的移动数据的整体式装置和非瞬时计算机可读介质
GB201220010D0 (en) * 2012-11-07 2012-12-19 Oxford Biotherapeutics Ltd Therapeutic amd diagnostic target
JP6681195B2 (ja) 2013-01-17 2020-04-15 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
ES2859604T3 (es) * 2013-10-11 2021-10-04 Oxford Bio Therapeutics Ltd Anticuerpos conjugados contra LY75 para el tratamiento del cáncer
TW201625692A (zh) 2014-11-14 2016-07-16 諾華公司 抗體藥物結合物
EP3465201A4 (en) 2016-06-06 2020-08-26 Astute Medical, Inc. MANAGEMENT OF ACUTE KIDNEY DAMAGE USING INSULINOMIMETIC GROWTH FACTOR BINDING PROTEIN 7 AND TISSUE METALLOPROTEINASE 2 INHIBITOR
GB201703876D0 (en) 2017-03-10 2017-04-26 Berlin-Chemie Ag Pharmaceutical combinations
GB201809746D0 (en) 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
BR112023023831A2 (pt) 2021-05-26 2024-01-30 Oxford Biotherapeutics Ltd Métodos, combinação farmacêutica, anticorpo ou porção de ligação ao antígeno do mesmo
US20250073346A1 (en) 2021-11-18 2025-03-06 Oxford Bio Therapeutics Ltd Pharmaceutical combinations

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
EP0216846B2 (en) 1985-04-01 1995-04-26 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0247091B1 (en) 1985-11-01 1993-09-29 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
AU622426B2 (en) 1987-12-11 1992-04-09 Abbott Laboratories Assay using template-dependent nucleic acid probe reorganization
DE768377T1 (de) 1988-09-02 1998-01-02 Dyax Corp Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68913658T3 (de) 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
GB9106048D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccines
DE69123848T2 (de) 1990-10-22 1997-07-10 Abbott Lab Stabile sauerstoff-freie reagenzienlösung für diagnostik
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
DE69233367T2 (de) 1991-04-10 2005-05-25 The Scripps Research Institute, La Jolla Bibliotheken heterodimerer rezeptoren mittels phagemiden
EP0590067A1 (en) 1991-06-14 1994-04-06 Xoma Corporation Microbially-produced antibody fragments and their conjugates
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
JP3949712B2 (ja) 1991-12-02 2007-07-25 メディカル リサーチ カウンシル 抗体セグメントレパートリー由来でファージに表示される抗自己抗体の産生
DK1024191T3 (da) 1991-12-02 2008-12-08 Medical Res Council Fremstilling af autoantistoffer fremvist på fag-overflader ud fra antistofsegmentbiblioteker
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ATE149570T1 (de) 1992-08-17 1997-03-15 Genentech Inc Bispezifische immunoadhesine
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
DE69333969T2 (de) 1992-10-30 2006-09-14 The General Hospital Corp., Boston Wechselwirkendes Fallensystem zur Isolierung von Proteinen
US5807683A (en) 1992-11-19 1998-09-15 Combichem, Inc. Combinatorial libraries and methods for their use
DK0698097T3 (da) 1993-04-29 2001-10-08 Unilever Nv Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde
JPH09506262A (ja) 1993-12-08 1997-06-24 ジェンザイム・コーポレイション 特異的抗体の製造方法
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
ES2247204T3 (es) 1994-01-31 2006-03-01 Trustees Of Boston University Bancos de anticuerpos policlonales.
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US5738996A (en) 1994-06-15 1998-04-14 Pence, Inc. Combinational library composition and method
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5616502A (en) 1995-05-19 1997-04-01 Molecular Probes, Inc. Non-specific protein staining using merocyanine dyes
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
GB9608510D0 (en) 1996-04-25 1996-07-03 Medical Res Council Calcium dependent binding ligands
WO1997045449A1 (en) 1996-05-29 1997-12-04 Derek Nigel John Hart Dendritic cell receptor
JP2002508652A (ja) * 1996-08-23 2002-03-19 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド 新規なヒト増殖因子
US6171816B1 (en) * 1996-08-23 2001-01-09 Human Genome Sciences, Inc. Human XAG-1 polynucleotides and polypeptides
GB9624927D0 (en) 1996-11-29 1997-01-15 Oxford Glycosciences Uk Ltd Gels and their use
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
GB9710582D0 (en) 1997-05-22 1997-07-16 Oxford Glycosciences Uk Ltd A method for de novo peptide sequence determination
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
PT2180007E (pt) 1998-04-20 2013-11-25 Roche Glycart Ag Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
WO2001057252A2 (en) 2000-02-04 2001-08-09 Aeomica, Inc. Methods and apparatus for high-throughput detection and characterization of alternatively spliced genes
CN100384875C (zh) * 2000-02-25 2008-04-30 牛津格莱克科学(英国)有限公司 蛋白质
GB0004576D0 (en) * 2000-02-25 2000-04-19 Oxford Glycosciences Uk Ltd Proteins
US6900016B1 (en) 2000-09-08 2005-05-31 Applera Corporation Polymorphisms in known genes associated with inflammatory autoimmune disease, methods of detection and uses thereof
KR100877676B1 (ko) 2000-10-06 2009-01-09 교와 핫꼬 기린 가부시키가이샤 항체 조성물을 생산하는 세포
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
DK1385538T3 (da) 2001-04-05 2013-04-29 Univ Johns Hopkins Kimære vacciner omfattende det lumenale domæne fra LAMP-1 eller LAMP-2
WO2002102235A2 (en) 2001-06-18 2002-12-27 Eos Biotechnology Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
ATE477280T1 (de) 2001-06-28 2010-08-15 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
WO2003042661A2 (en) 2001-11-13 2003-05-22 Protein Design Labs, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
JP2005525789A (ja) * 2001-11-13 2005-09-02 プロテイン デザイン ラブス インコーポレイティド ガンの診断方法、ガンのモジュレータのスクリーニング組成物及び方法
US20030170743A1 (en) * 2001-12-03 2003-09-11 Julie Carman Polynucleotides and polypeptides associated with the development of osteoarthritis
US20030215835A1 (en) * 2002-01-15 2003-11-20 Zairen Sun Differentially-regulated prostate cancer genes
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
EP1487857A4 (en) 2002-03-07 2006-08-09 Ludwig Inst Cancer Res BLOOD AND LYMPHATIC ENDOTHELIAL CELL GENES
EA200401325A1 (ru) 2002-04-09 2005-04-28 Киова Хакко Когио Ко., Лтд. Клетки с модифицированным геномом
CA2492092A1 (en) 2002-06-28 2004-01-08 Greg Winter Immunoglobin single variant antigen-binding domains and dual-specific constructs
AU2003256240A1 (en) 2002-08-29 2004-03-19 National University Of Singapore Recombinant nucleic acid useful for inducing protective immune response against allergens
AU2003291625B2 (en) 2002-09-16 2009-10-08 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
AU2002951409A0 (en) * 2002-09-16 2002-09-26 North Western Adelaide Health Services Methods for regulating cancer
AU2003286002B2 (en) 2002-11-08 2011-06-16 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
US20060281672A1 (en) 2002-12-06 2006-12-14 Hart Derek N J Dec-205 (ly 75)/dcl-1 intergenic splice variants associated with hodgkin's disease, and uses thereof
EP1578801A2 (en) 2002-12-27 2005-09-28 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
EP2357237A1 (en) 2003-05-14 2011-08-17 Domantis Limited A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire
CA2526339A1 (en) 2003-05-19 2005-02-24 Duke University Polyvalent immunogen
PT1639011E (pt) 2003-06-30 2009-01-20 Domantis Ltd Anticorpos (dab) de domínio único peguilados
WO2005019258A2 (en) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP1759010A4 (en) 2004-01-07 2008-12-24 Bristol Myers Squibb Co BIOMARKERS AND METHOD FOR DETERMINING SENSITIVITY AGAINST MODULATORS OF EGF (EPIDERMAL GROWTH FACTOR) RECEPTORS
WO2006093524A2 (en) * 2004-07-16 2006-09-08 The General Hospital Corporation Antigen-carbohydrate conjugates
WO2006034455A2 (en) * 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth
JP2008528010A (ja) 2005-01-31 2008-07-31 アブリンクス ナームローゼ フェンノートシャップ 重鎖抗体の可変ドメイン配列を作出する方法
EP1695981A1 (de) 2005-02-25 2006-08-30 Forschungsverbund Berlin e.V. Verfahren zum Redox-Potential-abhängigen Nachweis von Targetmolekülen durch wechselwirkende Polypeptide
US7608413B1 (en) 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof
RU2007145509A (ru) 2005-05-09 2009-06-20 Гликарт Биотехнологи Аг (Ch) Антигенсвязывающие молекулы, имеющие модифицированные fc-участки и измененное связывание с fc-рецепторами
WO2007030531A2 (en) 2005-09-06 2007-03-15 Molecular Image Inc. Reagents for testing and molecular imaging of liver cancer
US7842466B1 (en) * 2005-09-16 2010-11-30 Celera Corporation Colon disease targets and uses thereof
EA016609B1 (ru) 2005-11-28 2012-06-29 Генмаб А/С Рекомбинантные моновалентные антитела и способы их получения
GB0611116D0 (en) * 2006-06-06 2006-07-19 Oxford Genome Sciences Uk Ltd Proteins
EP2052088A2 (en) 2006-08-02 2009-04-29 Genizon Biosciences Genemap of the human genes associated with psoriasis
EP2057465A4 (en) 2006-08-09 2010-04-21 Homestead Clinical Corp ORGANIC PROTEINS AND METHOD OF USE THEREOF
WO2008104803A2 (en) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
EA201692127A1 (ru) 2007-11-07 2017-08-31 Селлдекс Терапьютикс Инк. Антитела, связывающиеся с человеческим dec-205
US8168586B1 (en) 2007-11-21 2012-05-01 Celera Corporation Cancer targets and uses thereof
DE102008006841B4 (de) 2008-01-30 2013-07-11 Wolfram Kangler Verfahren und Vorrichtung zum Betrieb einer Brennkraftmaschine mit einem flüssigen Kraftstoffgemisch
EP2159291A1 (en) 2008-09-01 2010-03-03 Agendia B.V. Means and method for determining tumor cell percentage in a sample
US20120128642A1 (en) 2009-07-23 2012-05-24 Jeffrey Keeler Teumer Potency markers
US9002545B2 (en) 2011-01-07 2015-04-07 Wabtec Holding Corp. Data improvement system and method

Also Published As

Publication number Publication date
CY1122048T1 (el) 2020-10-14
DK3118221T3 (da) 2019-09-23
WO2008104804A3 (en) 2009-03-26
WO2008104806A2 (en) 2008-09-04
LT3118220T (lt) 2019-10-10
HRP20191609T1 (hr) 2019-12-13
HUE030894T2 (en) 2017-06-28
PT3118220T (pt) 2019-09-27
US20100098626A1 (en) 2010-04-22
US20100098627A1 (en) 2010-04-22
EP2441775B1 (en) 2016-08-17
US20160175437A1 (en) 2016-06-23
PT2441775T (pt) 2016-11-04
DK3118220T3 (da) 2019-09-23
ES2599477T3 (es) 2017-02-01
WO2008104806A3 (en) 2009-03-19
LT2441775T (lt) 2016-10-25
EP2441775A1 (en) 2012-04-18
ES2745014T3 (es) 2020-02-27
US9200055B2 (en) 2015-12-01
EP2122360A2 (en) 2009-11-25
EP3118220B1 (en) 2019-08-21
WO2008104803A2 (en) 2008-09-04
SI2441775T1 (sl) 2016-12-30
HRP20161338T1 (hr) 2016-12-16
WO2008104804A2 (en) 2008-09-04
JP2015091797A (ja) 2015-05-14
JP2010518847A (ja) 2010-06-03
PL3118220T3 (pl) 2020-02-28
CY1118169T1 (el) 2017-06-28
US20100098628A1 (en) 2010-04-22
WO2008104803A3 (en) 2009-01-15
EP3118220A1 (en) 2017-01-18
DK2441775T3 (en) 2016-10-03
HUE046149T2 (hu) 2020-02-28
PL2441775T3 (pl) 2017-02-28
SI3118220T1 (sl) 2019-11-29

Similar Documents

Publication Publication Date Title
JP5945381B2 (ja) タンパク質
US8540998B2 (en) Methods for treating cancer using ephrin type-A receptor 10 antibodies conjugated to cytotoxic agents
US20210325396A1 (en) Identification of protein associated with hepatocellular carcinoma, glioblastoma and lung cancer
US8420091B2 (en) Matriptase protein and uses thereof
US8084034B2 (en) Proteins
US20100284918A1 (en) Protein
US8535677B2 (en) Antibody drug conjugate treatment of colorectal cancer
US20110229480A1 (en) Pta072 protein
EP2447719A1 (en) Proteins
US20110195074A1 (en) Ephrin Type-A Receptor 7 Protein
US20120058131A1 (en) Pta089 protein
EP2122359A2 (en) Proteins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130926

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141009

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20141202

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20150206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160307

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160530

R150 Certificate of patent or registration of utility model

Ref document number: 5945381

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250